VIVACITY-MG: A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE- BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY, TOLERABILITY, EFFICACY, PHARMACO-KINETICS, PHARMACODYNAMICS, AND IMMUNOGENICITY OF NIPOCALIMAB ADMINISTERED TO ADULTS WITH GENERALIZED MYASTHENIA GRAVIS

被引：0
|
作者：
Antozzi, Carlo [1 ]
Guptill, Jeffrey [2 ]
Bril, Vera [3 ]
Gamez, Josep [4 ]
Meuth, Sven G. [5 ]
Blanco, Jose L. M. [6 ]
Nowak, Richard J. [7 ]
Quan, Dianna [8 ]
Sevilla, Teresa [9 ]
Szczudlik, Andrzej [10 ]
Hegarty, Brooke [11 ]
Jouvin, Marie-Helene [11 ]
Jin, Jim [11 ]
Arroyo, Santiago [11 ]
机构：
[1] Fdn Ist Neurol Carlo Besta, Milan, Italy
[2] Duke Univ, Sch Med, Durham, NC USA
[3] Univ Toronto, Div Neurol, Toronto, ON, Canada
[4] Hosp Univ Vall Hebron, Neuromuscular Unit, Barcelona, Spain
[5] Heinrich Heine Univ Dusseldorf, Dusseldorf, Germany
[6] Hosp Gen Univ Gregorio Maranon, Serv Neurol, Madrid, Spain
[7] Yale Univ, Sch Med, New Haven, CT USA
[8] Univ Colorado, Sch Med, Aurora, CO USA
[9] Hosp Univ Politecn La Fe, Valencia, Spain
[10] Jagiellonian Univ, Med Coll, Krakow, Poland
[11] Momenta Pharmaceut, Cambridge, MA USA
来源：
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY | 2023年 / 41卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P-119
引用
收藏
页码：498 / 498
页数：1
相关论文
共 50 条
  • [41] DESIGNING OF A PHASE 2, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLEBLIND STUDY TO ASSESS THE EFFICACY AND SAFETY OF NIPOCALIMAB, AN FCRN INHIBITOR, IN ADULTS WITH PRIMARY SJOGREN'S SYNDROME
    Hubbard, J.
    Campbell, K.
    Sivils, K.
    Hoffman, R.
    Lo, K. H.
    Leu, J. H.
    Bowman, S.
    Liva, S.
    Zuraw, Q.
    Stevens, A. M.
    Ling, L.
    Karcher, K.
    Ramchandren, S.
    Sun, H.
    Scofield, R. H.
    Seror, R.
    Wallace, D. J.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 892 - 893
  • [42] A randomized, double-blind, multicenter, placebo-controlled phase III trial to evaluate the efficacy and safety of pregabalin in Japanese patients with fibromyalgia
    Hiroyoshi Ohta
    Hiroshi Oka
    Chie Usui
    Masayuki Ohkura
    Makoto Suzuki
    Kusuki Nishioka
    Arthritis Research & Therapy, 14
  • [43] A randomized, double-blind, multicenter, placebo-controlled phase III trial to evaluate the efficacy and safety of pregabalin in Japanese patients with fibromyalgia
    Ohta, Hiroyoshi
    Oka, Hiroshi
    Usui, Chie
    Ohkura, Masayuki
    Suzuki, Makoto
    Nishioka, Kusuki
    ARTHRITIS RESEARCH & THERAPY, 2012, 14 (05)
  • [44] Double-blinded, randomized, placebo-controlled phase 2 study of FCRN antagonist batoclimab in Chinese generalized myasthenia gravis
    Zhao, Chongbo
    Yan, Chong
    Yang, Huan
    Li, Haifeng
    Duan, Ruisheng
    Zou, Zhangyu
    Zhou, Hongyu
    Zhang, Hua
    Lee, Michael
    Chen, Emily
    Chen, Xiaoxiang
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2021, 429
  • [45] A PHASE 2, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, ASCENDING DOSE STUDY TO EVALUATE EFFICACY, SAFETY, AND TOLERABILITY OF CC 220 IN SUBJECTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
    Furie, R.
    Werth, V. P.
    Lee, E.
    Box, E.
    Fondal, M.
    Kivitz, A.
    Chatham, W. W.
    Kalunian, K. C.
    Legerton, C.
    Anolik, J. H.
    Korish, S.
    Hough, D. R.
    Weiswasser, M.
    Choi, S.
    Schafer, P.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2016, 34 (04) : S77 - S77
  • [46] A randomized, double- blind, placebo-controlled, phase 3 study to evaluate the safety and efficacy of XEN1101 as an adjunctive therapy in the treatment of primary generalized tonic-clonic seizures
    Gil-Nagel Rein, A.
    Vossler, D.
    Ben-Menachem, E.
    LaFrance, W. C., Jr.
    Harden, C.
    Qian, J.
    Beatch, G. N.
    Kenney, C.
    EPILEPSIA, 2023, 64 : 17 - 18
  • [47] A Phase 2/3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant for the Preventive Treatment of Migraine
    Croop, R.
    Lipton, R. B.
    Kudrow, D.
    Stock, D. A.
    Kamen, L.
    Conway, C. M.
    Stock, E. G.
    Coric, V.
    Goadsby, P. J.
    CEPHALALGIA, 2021, 41 (1_SUPPL) : 28 - 29
  • [48] A phase 2/3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of rimegepant for the preventive treatment of migraine
    Croop, R.
    Lipton, R. B.
    Kudrow, D.
    Stock, D. A.
    Kamen, L.
    Conway, C. M.
    Stock, E. G.
    Coric, V
    Goadsby, P. J.
    HEADACHE, 2021, 61 : 98 - 99
  • [49] A Phase 2/3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant for the Preventive Treatment of Migraine
    Croop, Robert
    Lipton, Richard
    Thiry, Alexandra
    Kamen, Lisa
    Coric, Vlad
    Goadsby, Peter
    NEUROLOGY, 2021, 96 (15)
  • [50] A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of AMG 334 for the Prevention of Episodic Migraine
    Sun, H.
    Silberstein, S.
    Dodick, D. W.
    Reuter, U.
    Ashina, M.
    Saper, J. R.
    Cady, R.
    Chon, Y.
    Dietrich, J.
    Lenz, R.
    HEADACHE, 2015, 55 : 132 - 132
12345